Waters Corporation reported second-quarter earnings per share of $3.05, exceeding the $3.04 consensus estimate. The solid earnings result underscores the company's strong momentum and an increased revenue guidance that positions it favorably for continued investment growth.

Key Highlights

  • Waters Corporation (NYSE: WAT) has announced second-quarter earnings of $3.05 per share for the period ending July 4, 2026, slightly surpassing the consensus estimate of $3.04.
  • In response to current market dynamics, Waters has raised its full-year 2026 revenue guidance to a range between $6.415 billion and $6.476 billion.
  • Market capitalization stands at approximately $37.3 billion, within a 52-week range of $275.05 to $414.15.

Waters Corporation (NYSE: WAT) has announced second-quarter earnings of $3.05 per share for the period ending July 4, 2026, slightly surpassing the consensus estimate of $3.04. The strong performance highlights the company's strong positioning in the market, with growing momentum driving positive results across its divisions. This performance indicates investor confidence in Waters as it adjusts its full-year outlook based on continued market strength.

Incremental Revenue Growth

The increase in revenues across the board, including $368 million for the Biosciences Division and $449 million for the Advanced Diagnostics Division, demonstrates favorable trends in customer demand and market expansion. Such performance illustrates the effectiveness of Waters' growth strategies and enhances investor outlook.

Strong Forward Guidance

In response to current market dynamics, Waters has raised its full-year 2026 revenue guidance to a range between $6.415 billion and $6.476 billion. This includes an organic constant currency revenue growth forecast of 7.0% to 9.0%. The company also expects its adjusted EPS for the year to fall between $14.45 and $14.65, marking a substantial year-over-year growth rate of 10% to 12%.

The raised guidance reflects Waters' strategic positioning amid a backdrop of strengthening end market conditions, which is likely to bolster investor confidence moving forward.

Positive Market Reception

Market capitalization stands at approximately $37.3 billion, within a 52-week range of $275.05 to $414.15. These performance metrics reflect a reaffirmation of shareholder confidence as the demand across various market segments continues to accelerate. While sector peers like TMO, DHR, and A have seen declines today, Waters remains a notable outlier with its strong results, emphasizing the importance of its operational growth against broader market trends.

Upcoming Financial Results

Investors will look forward to the release of Waters' third-quarter results, scheduled for later this year. How the company performs in this next critical reporting period will shed additional light on its trajectory and further inform investor strategies.

Peers Moving on This News

  • Thermo Fisher Scientific Inc (TMO) down 1.9%
  • Danaher Corp (DHR) down 1.4%
  • Agilent Technologies Inc (A) down 1.3%

Analysis based on the Form 8-K filed 4 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.